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Objective: Enamel matrix derivative (EMD) is used clinically to promote periodontal tissue regeneration. However, the effects of EMD on gingival epithelial cells during 
regeneration of periodontal tissues are unclear. In this in vitro study, we purified ameloblastin 
from EMD and investigated its biological effects on epithelial cells. Material and Methods: 
Bioactive fractions were purified from EMD by reversed-phase high-performance liquid 
chromatography using hydrophobic support with a C18 column. The mouse gingival epithelial 
cell line GE-1 and human oral squamous cell carcinoma line SCC-25 were treated with 
purified EMD fraction, and cell survival was assessed with a WST-1 assay. To identify the 
proteins in bioactive fractions of EMD, we used proteome analysis with two-dimensional 
gel electrophoresis followed by identification with liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) analysis. Results: Purified fractions from EMD suppressed 
proliferation of GE-1 and SCC-25. LC-MS/MS revealed that ameloblastin in EMD is the 
component responsible for inhibiting epithelial cell proliferation. The inhibitory effect of 
ameloblastin on the proliferation of GE-1 and SCC-25 was confirmed using recombinant 
protein. Conclusion: The inhibitory effects of EMD on epithelial cell proliferation are caused 
by the biological activities of ameloblastin, which suggests that ameloblastin is involved in 
regulating epithelial downgrowth in periodontal tissues.
Keywords: Periodontitis. Periodontal guided tissue regeneration. Epithelial cells. Dental 
enamel proteins.
INTRODUCTION
Periodontitis is an inflammatory process caused 
by bacterial components and products that trigger 
the production of inflammatory molecules from cells 
in periodontal tissues. Cells in gingival connective 
tissue are targets for bacterial virulence factors and 
inflammatory mediators18. These factors stimulate 
gingival fibroblasts, macrophages, and lymphocytes 
to produce other inflammatory mediators, such as 
proinflammatory cytokines and prostanoids, which 
in turn induce matrix metalloproteinase production 
and activation, leading to extracellular matrix 
degradation9,22.
The primary aims of periodontal therapy are 
to control periodontal tissue inflammation and 
regain supporting tissue lost as a consequence of 
periodontal disease. Enamel matrix derivative (EMD) 
is beneficial in healing wounds and regeneration and 
is widely used to treat periodontal damage caused 
by periodontitis, as it promotes tissue regeneration 
and decreases inflammation after periodontal 
surgery12.
EMD is extracted from developing porcine 
embryonic enamel and contains hydrophobic 
enamel matrix proteins12 which are mainly 
composed of amelogenin and related proteins6,7,21. 
These proteins are important in the development of 
acellular cementum, the periodontal ligament, and 
alveolar bone. EMD has a variety of biological effects 
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in vitro, such as regeneration of mesenchymal and 
epithelial cells, enhancement of wound healing via 
extracellular matrix synthesis, and the regulation 
of molecules involved in bone remodeling1,8. 
Genome-wide microarray approach demonstrated 
that EMD causes substantial alternations in gene 
expression, with similar patterns observed in palatal 
and gingival fibroblasts11.
It has been reported that EMD stimulated 
osteoclastogenesis via the NF-kappa B14 receptor 
activator,20 or transforming growth factor-beta1 
signaling10. These results suggest that EMD provides 
a local environment suitable for bone regeneration 
in periodontal tissues because of its effects on 
bone remodeling activities such as bone formation 
and resorption. Furthermore, previous studies 
demonstrated that EMD inhibited the proliferation 
of primary human gingival keratinocytes29. However, 
the effects of EMD on gingival epithelial cells during 
regeneration of periodontal tissues are unclear. In 
this in vitro study, we purified ameloblastin from 




The mouse gingival epithelial cell line GE-1 was 
obtained from the Riken Cell Bank (Ibaraki, Japan). 
Cells were maintained in a serum-free medium 
(SFM-101; Nissui, Tokyo, Japan) supplemented with 
1% fetal bovine serum (FBS; Gibco, Grand Island, 
NY, USA), penicillin G (100 U/mL), streptomycin 
(100 μg/mL), and epithelial growth factor (EGF; 
1 μg/mL). SCC-25 cells, which are derived from 
human squamous cell carcinoma of the tongue, 
were obtained from DS Pharmaceutical Co. 
(Osaka, Japan) and maintained in a 1:1 mixture of 
Dulbecco’s modified Eagle’s medium (DMEM) and 
Ham’s F-12 medium supplemented with 10% FBS.
Purification of EMD
EMD (Biora, Malmö, Sweden) was kindly 
supplied by Seikagaku Corporation (Tokyo, 
Japan). Lyophilized material was dissolved in 
0.1% trifluoroacetic acid (TFA) (30 mg/mL), after 
which reversed-phase high-performance liquid 
chromatography (HPLC) was performed using 
a Waters system (Midford, MA, USA) and C18 
column (4.6×150 mm; Vydac, Hesperia, CA, USA) 
equilibrated with 0.1% TFA. Fractions of 0.5 mL 
were collected at a flow rate of 0.5 mL/minute and 
assayed for epithelial cell proliferation, as described 
below. Protein content was determined using a Bio-
Rad protein assay reagent (Bio-Rad Laboratories, 
Richmond, CA, USA). Bioactive fractions that 
inhibited epithelial cell proliferation in the WST-1 
assay were lyophilized, dissolved in the culture 
medium, and used in the cell culture assays.
Expression and purification of recombinant 
ameloblastin
The expression vector pcDNA3.1 was used to 
express FLAG-tagged human ameloblastin proteins, 
as previously described13. Expression plasmids were 
transfected into COS-7 cells by Nucleofection™ 
using a 4D Nucleofector™ device (Lonza Japan Inc., 
Tokyo, Japan). After 2 days, transfected cells were 
lysed with lysis buffer (50 mM Tris-HCl containing 
150 mM NaCl, 1 mM EDTA, and 1% Triton X, pH 
7.4), and FLAG-tagged recombinant protein was 
partially purified with ANTI-FLAG® M2 Affinity Gel 
(Invitrogen, Grand Island, NY, USA), according to 
the manufacturer’s instructions.
WST-1 analysis
Cell viability was determined using tetrazolium 
salt WST-1 (4-[3-(4-iodophenyl)-2H-5-tetrazolium]-
1-3-benzene disulfonate; Wako Pure Chemical 
Industries, Ltd., Japan). GE-1 cells were plated in 
96-well plates at a concentration of 1×104 cells/
well 3 hours before starting the experiment. Later, 
cells were stimulated with fractioned EMD or 
recombinant protein. After stimulated cells were 
cultured for 44 hours, WST-1 solution (10 μL) 
was added to each well, followed by incubation 
for 4 hours. Absorbance at 450 and 630 nm was 
measured using a Multiskan JX Microplate Reader 
(Thermo Electron Co., Kanagawa, Japan).
Silver stain
HPLC-purified fractions were solubilized in lysis 
buffer (75 mM Tris-HCl containing 2% SDS and 
10% glycerol, pH 6.8), then boiled for 5 minutes 
before electrophoresis. Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) 
was performed on 12.5% gels that were stained 
with 2D-Silver Stain (Daiichi Pure Chemicals Co., 
Tokyo, Japan), according to the manufacturer’s 
instructions.
Protein identification
SDS-PAGE was done on 5-20% acrylamide 
gradient gels and visualized with silver stain. Single 
protein bands were cut after electrophoresis, after 
which the gel portion containing the protein was 
de-stained and washed with a 100-mM ammonium 
bicarbonate/acetonitrile 1:1 (v/v) solution for 20 
minutes (with shaking), dried at room temperature 
for 30 minutes, and rehydrated with a reducing 
solution (10 mM EDTA, 10 mM dithiothreitol, 100 
mM NH4HCO3). The gel portion was alkylated by 
iodoacetamide. Enzymatic cleavage was initiated by 
adding a 50-mM ammonium bicarbonate solution 
containing trypsin (Promega, Lyon, France) and 
lysylendopeptidase (LEP; Wako Pure Chemical 
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Industries, Ltd., Osaka, Japan). After absorption 
of the protease solution, aliquots (10 µL) of 50 
mM ammonium bicarbonate solution containing 
5 mM calcium chloride were added sequentially 
and digested for 16 hours at 37°C. To recover 
hydrophobic peptides, the samples were extracted 
using 50% acetonitrile containing 2.5% formic 
acid. Pooled extracts were concentrated using a 
centrifugal concentrator and then desalted using a 
ZipTip µC18 (Millipore, Bedford, MA, USA).
Peptides were resolved with 3 µL of 75% 
acetonitrile/H2O (v/v) containing 0.1% trifluoroacetic 
acid and then diluted with 12 µL of 1% formic acid. 
The digestion mixture was applied to a reversed-
phase column (Zorbax 300S-C18, 3.5 µm, 150×0.3 
mm, Agilent, Santa Clara, CA, USA) in a capillary 
HPLC (Agilent 1100 system, Agilent). The column 
was eluted with a gradient of 10-65% acetonitrile 
in 0.1% formic acid at a flow rate of 4 µL/minutes. 
Ion-trap mass spectrometry (LC-MS/MS) was 
performed with an HCT Ultra SI (Bruker Daltonics, 
Bremen, Germany), according to the manufacturer’s 
instructions. MS/MS spectra were searched against 
a protein database provided by the Swiss Institute 
of Bioinformatics, using the MASCOT MS/MS ions 
search server (Matrix Science, Boston, MA, USA).
Statistical analysis
All data was obtained from at least three 
independent experiments, each performed in 
Figure 1- Effects of purified enamel matrix derivative (EMD) fractions on epithelial cell proliferation. (A) Results of reversed-
phase high-performance liquid chromatography (HPLC) using C18 hydrophobic support. Lyophilized EMD was dissolved 
in 0.1% TFA, applied to reversed-phase HPLC, and eluted at 0.5 mL/minute. The arrow indicates the bioactive peak; 
(B) GE-1 cells were stimulated with each fraction (50 μg/mL) for 48 hours. Cell viability was determined using WST-1 
analysis. The data show the percentage inhibition of cell proliferation from independent samples (n=3). The bars represent 
mean±standard deviation. Data was analyzed by Dunnett’s test after one-way ANOVA (*P<0.05, **P<0.01, ***P<0.0001 
vs untreated control); (C) GE-1 and SCC-25 cells were separately cultured for 48 hours in the presence of 0-50 μg/mL of 
bioactive fraction number 14, after which cell viability was determined using WST-1 analysis. The data shows the percent 
inhibition of cell proliferation from independent samples (n=3). The bars represent mean±standard deviation. Data was 
analyzed by Dunnett’s test after one-way ANOVA (**P<0.01, ***P<0.0001 vs untreated control); (D) Proteins of each 
fraction (numbers 11–18) were visualized by SDS-PAGE followed by silver staining
KURAMITSU-FUJIMOTO S, ARIYOSHI W, SAITO N, OKINAGA T, KAMO M, ISHISAKI A, TAKATA T, YAMAGUCHI K, NISHIHARA T
2015;23(1):49-55
J Appl Oral Sci. 52
triplicate. Statistical analyses were conducted 
using JMP® software, version 10.0.2 (SAS Institute 
Inc., Cary, NC, USA). All data was expressed as 
mean±standard deviation and analyzed by one-way 
analysis of variance (ANOVA) followed by Dunnett’s 
post test. A P value of less than 0.05 was considered 
to indicate statistical significance.
RESULTS
Effects of purified fractions of EMD on 
epithelial cell proliferation
As shown in Figure 1A, both major and minor 
peaks were detected, and 0.5-mL fractions 
were collected at a flow rate of 0.5 mL/minute, 
lyophilized, and dissolved in the culture medium. To 
determine the effects on cell viability, epithelial cells 
were treated with purified EMD fraction (numbers 
1-40) for 44 hours, after which cell survival was 
assessed with a WST-1 assay. Culturing with 
each fraction (numbers 10-18) suppressed the 
proliferation of epithelial cells, whereas the other 
fractions had no effect on cell growth (data not 
shown). Among the fractions, number 14 had the 
highest inhibitory activity against GE-1 cells (Figure 
1B) and also significantly inhibited proliferation of 
SCC-25 cells in a dose-dependent manner up to 50 
µg/mL (Figure 1C). Silver staining revealed 15-20 
kDa proteins in fraction 14 (Figure 1D), which was 
eluted with 35% acetonitrile in 0.1% TFA.
Proteome analysis of bioactive fractions 
of EMD
To identify the proteins in bioactive fractions 
of EMD, we used proteome analysis with two-
dimensional gel electrophoresis (2DE) followed by 
identification with mass spectrometry. Figure 2A 
shows the separate proteins extracted from the 
bioactive EMD fractions by 2DE and SDS-PAGE. 
Some of the proteins were resolved on SDS-PAGE 
gels, the most abundant of which had a molecular 
mass of approximately 17 kDa. A total of 5 spots 
were chosen (Figure 2B) and analyzed for protein 
identification. As shown in Figure 3, fraction 14-3 
Figure 2- Proteome analysis of bioactive enamel matrix derivative (EMD) fractions. (A) Separation of proteins in bioactive 
EMD fractions and visualization of protein bands by silver staining. The vertical axis represents molecular mass (kDa); (B) 
Semiquantitative variation of protein spots among bioactive EMD fractions
Sample Accession Identified Protein Sequence
Fr12-1 - ND -
Fr13-1 - ND -
Fr14-1 - ND -
Fr14-2 - Serum albumin -
Fr14-3 Q28989 Ameloblastin EHETQQPSLQPQQPGQK
ND=not detected
Figure 3- Identified peptides in protein spots among bioactive fractions of enamel matrix derivative (EMD) by LC-MS/MS.
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contained ameloblastin.
Effects of recombinant ameloblastin on 
epithelial cell proliferation
To examine the role of ameloblastin on epithelial 
cell growth, we used affinity gel to create FLAG-
tagged recombinant ameloblastin. Proliferation of 
GE-1 (Figure 4A) and SCC-25 (Figure 4B) cells was 
inhibited in a dose-dependent manner when the 
cells were cultured with recombinant ameloblastin.
DISCUSSION
We found that EMD inhibited the proliferation of 
mouse gingival epithelial and human oral squamous 
carcinoma cells. These findings are consistent with 
those of a previous study, which reported dose-
dependent inhibition of oral epithelial cell division 
by EMD16. To investigate the effects of EMD on the 
proliferation of gingival epithelial cells, we examined 
the biological and chemical properties of EMD.
Bioactive fractions that inhibited epithelial cell 
proliferation were purified using reversed-phase 
HPLC and a C18 column. As shown in Figure 1A, 
fractions that inhibited epithelial cell proliferation 
were detected as minor peaks, after elution with 
31% acetonitrile in 0.1% TFA. These bioactive 
fractions also inhibited the proliferation of GE-1 
and SCC-25 cells (Figure 1B and 1C). Our findings 
indicate that EMD contains bioactive molecules that 
suppress epithelial proliferation. Furthermore, SDS-
PAGE analysis showed that EMD contains several 
proteins and peptides with molecular weights of 
15-20 kDa (Figure 1D).
To identify the molecules that inhibit epithelial cell 
proliferation, the bioactive fractions were separated 
using 2DE and identified using MS. Proteomics with 
2DE, MS, and database searches are a powerful 
method for determining the composition of 
complex combinations of proteins2,4. We identified 
ameloblastin in bioactive EMD fractions (Figures 2 
and 3). Previous studies noted that EMD contains 
glycoprotein, amelogenin, and non-amelogenin 
proteins (e.g., ameloblastin and enamelin) at a 
ratio of approximately 90:1024,25, which suggests 
that ameloblastin is a minor component with high 
biological activity.
Ameloblastin, also known as amelin or sheathlin, 
is the most abundant non-amelogenin enamel matrix 
protein3,5,17. Recently, endogenous ameloblastin has 
been identified in many non-dental tissues including 
mandibular alveolar bones and basal bones but also 
in several soft tissues including eyes, tongues and 
testicles15. These findings suggest that ameloblastin 
functions as growth factor-like molecule and has 
an important role beyond the control of enamel 
mineralization. However, less attention has been 
paid to the effects of ameloblastin on epithelial 
cell proliferation. To explore the potential functions 
of ameloblastin in epithelial cell proliferation, we 
purified FLAG-tagged recombinant proteins in this 
study.
Recombinant ameloblastin inhibited epithelial cell 
proliferation in vitro (Figure 4). Our results suggest 
that ameloblastin is the principal bioactive factor in 
EMD in inhibiting epithelial cell proliferation. Recent 
study revealed that lower a concentration (12.5-100 
ng/ml) of recombinant human ameloblastin purified 
using HaloTag® fusion tag system suppressed 
the proliferation of SCC-25 cells23. We have no 
ready explanation for these discrepancies, though 
it is possible that they reflect differences in the 
purification procedure of recombinant protein. 
However, a previous study showed that EMD 
stimulated proliferation of human periodontal 
Figure 4- Effects of recombinant ameloblastin on 
epithelial cell proliferation. GE-1 (A) and SCC-25 (B) 
cells were separately stimulated with recombinant 
ameloblastin protein for 48 hours, after which cell viability 
was determined using WST-1 analysis. The data shows 
the percent inhibition of cell proliferation from independent 
samples (n=3). The bars represent mean±standard 
deviation. Data was analyzed by Dunnett’s test after one-
way ANOVA (**P<0.01, ***P<0.0001 vs untreated control)
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cells, as well as epithelial cell rests of Malazzez, 
gingival fibroblasts, and osteoblasts9. In addition, 
recombinant ameloblastin has been shown to 
stimulate the proliferation of human mesenchymal 
stem cells and osteoblasts26. Together, these 
findings indicate that the effect of ameloblastin 
on cell proliferation varies according to cell 
type. Additional experiments using recombinant 
molecules are needed in order to clarify the cell-
specific activities of these fractions. Previous studies 
have provided some information on the role of 
ameloblastin in adhesion and proliferation in various 
cell types13,27,28,30.
Our findings are strongly supported by the 
previous studies in which the proliferation of SCC-25 
cells was shown to be inhibited via cell cycle arrest 
at G1 phase in response to EMD16 or ameloblastin23. 
Furthermore, the binding of enamel matrix proteins 
to specific proteins including fibronectin and type I 
collagen regulates their adhesive properties, leading 
to modulate fibroblast adhesion to epithelial cells19. 
Additional molecular studies are required in order 
to better understand the specific signaling pathway 
for ameloblastin in epithelial cells.
The ideal agent for promoting periodontal 
regeneration would not only stimulate regeneration 
of connective and bone tissues but also inhibit 
epithelial downgrowth, which frequently interferes 
with formation of a new connective tissue 
attachment. Our results show that ameloblastin 
inhibits epithelial cell proliferation, indicating that 
it may be important in periodontal tissue repair.
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